Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 15/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985430 | 0.92 | AOC3 (0.39) | AOC3ALDH1A1RXFP1NPC1RAB9A | |
| SCHEMBL4991741 | 0.89 | AOC3 (0.45) | AOC3ALDH1A1SMN1; SMN2 | |
| SCHEMBL4871391 | 0.89 | AOC3 (0.39) | AOC3 | |
| SCHEMBL4986164 | 0.87 | AOC3 (0.35) | AOC3 | |
| SCHEMBL4876400 | 0.86 | KMT2A (0.38) | AOC3ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4877774 | 0.86 | NPC1 (0.38) | AOC3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4864969 | 0.85 | SCD (0.42) | AOC3ALDH1A1RXFP1NPC1RAB9A | |
| SCHEMBL4986021 | 0.85 | AOC3 (0.34) | AOC3ALDH1A1RXFP1 | |
| SCHEMBL4988080 | 0.84 | NAMPT (0.36) | AOC3FLT1KDR | |
| SCHEMBL4982248 | 0.83 | AOC3 (0.34) | AOC3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885ALDH1A1 927/4885FLT1 7/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AOC3 85/4885ALDH1A1 260/4885FLT1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.